12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research

Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst.

Related Keywords

Stockholm ,Sweden ,Budapest ,Hungary ,Morten Henneveld ,National Center ,Metrics Inc ,Company Certified Adviser Is Carnegie Investment Bank ,Buda Health Clinic ,Biomedical Journal Of Scientific Technical Research ,Ossdsign Catalyst ,Biomedical Journal ,Technical Research ,Transforaminal Lumbar Interbody Fusion ,Medical Metrics ,Oswestry Disability Index ,Adverse Events ,Dsign Catalyst ,Spinal Disorders ,Certified Adviser ,Carnegie Investment Bank ,Nasdaq First North Growth Market ,